A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer

1. Martin, M.
2. Blasinska-Morawiec, M.
3. Salas, J.F.
4. Falcon, S.
5. Rolski, J.
6. Ferrari, B.L.
7. Gulyas, S.
8. Liu, Y.
9. Benhadji, K.A.